143 related articles for article (PubMed ID: 6788370)
1. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
3. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.
Garattini E; Colombo T; Donelli MG; Catalani P; Bianchi M; D'Incalci M; Pantarotto C
Cancer Chemother Pharmacol; 1983; 11(1):51-5. PubMed ID: 6411375
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Ames MM; Powis G; Kovach JS; Eagan RT
Cancer Res; 1979 Dec; 39(12):5016-21. PubMed ID: 115586
[TBL] [Abstract][Full Text] [Related]
5. Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism.
Klippert PJ; Hulshoff A; Mingels MJ; Hofman G; Noordhoek J
Cancer Res; 1983 Jul; 43(7):3160-4. PubMed ID: 6406053
[TBL] [Abstract][Full Text] [Related]
6. First-pass metabolism of pentamethylmelamine in the rat liver.
Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of hexamethylmelamine administered via the Ip route in an oil emulsion vehicle.
Wickes AD; Howell SB
Cancer Treat Rep; 1985 Jun; 69(6):657-62. PubMed ID: 3926309
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.
Dubois J; Atassi G; Hanocq M; Abikhalil F
Cancer Chemother Pharmacol; 1986; 18(3):226-30. PubMed ID: 3100080
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.
D'Incalci M; Farina P; Sessa C; Mangioni C; Garattini S
Cancer Treat Rep; 1982 Feb; 66(2):231-5. PubMed ID: 6799199
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits.
Gordon IL; Kar R; Opfell RW; Wile AG
Cancer Res; 1987 Oct; 47(19):5070-3. PubMed ID: 3113728
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.
Dubois J; Atassi G; Hanocq M; Abikhalil F
Cancer Chemother Pharmacol; 1988; 22(4):282-8. PubMed ID: 3139314
[TBL] [Abstract][Full Text] [Related]
12. Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.
Garattini E; Broggini M; Coccia P; Colombo T; Rossi C; D'Incalci M
Biochem Pharmacol; 1984 Sep; 33(17):2715-22. PubMed ID: 6431992
[TBL] [Abstract][Full Text] [Related]
13. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine.
Paolini A; D'Incalci M
Cancer Treat Rep; 1986 Apr; 70(4):513-6. PubMed ID: 3084083
[TBL] [Abstract][Full Text] [Related]
14. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.
Rutty CJ; Newell DR; Muindi JR; Harrap KR
Cancer Chemother Pharmacol; 1982; 8(1):105-11. PubMed ID: 6807560
[TBL] [Abstract][Full Text] [Related]
15. Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in-vivo data.
Borm PJ; Frankhuyzen-Sierevogel AC; Weller EB; Noordhoek J
J Pharm Pharmacol; 1985 Sep; 37(9):629-36. PubMed ID: 2867183
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent pharmacokinetics of PMM in the rat.
Colombo T; Torti L; D'Incalci M
Cancer Chemother Pharmacol; 1981; 5(3):201-3. PubMed ID: 6794923
[TBL] [Abstract][Full Text] [Related]
17. Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.
Brindley C; Gescher A; Langdon SP; Broggini M; Colombo T; D'Incalci M
Biochem Pharmacol; 1982 Mar; 31(5):625-31. PubMed ID: 6805472
[TBL] [Abstract][Full Text] [Related]
18. Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine.
Ames MM; Sanders ME; Tiede WS
Cancer Res; 1983 Feb; 43(2):500-4. PubMed ID: 6401219
[TBL] [Abstract][Full Text] [Related]
19. Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
D'Incalci M; Erba E; Balconi G; Morasca L; Garattini S
Br J Cancer; 1980 Apr; 41(4):630-5. PubMed ID: 6770884
[TBL] [Abstract][Full Text] [Related]
20. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
Judson IR; Rutty CJ; Abel G; Graham MA
Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
